Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.

Journal of neuro-oncology - 1 Feb 2017

Zhang Jie, Yao Tsun-Wen, Hashizume Rintaro, Hariono Sujatmi, Barkovich Krister J, Fan Qi-Wen, Prados Michael, James C David, Weiss William A, Nicolaides Theodore

Abstract excerpt

BRAFV600E is a common finding in glioma (about 10-60% depending on histopathologic subclassification). BRAFV600E monotherapy shows modest preclinical efficacy against BRAFV600E gliomas and also induces adverse secondary skin malignancies. Here, we examine the molecular mechanism of intrinsic resistance to BRAFV600E inhibition in glioma. Furthermore, we investigate BRAFV600E/MEK combination therapy that overcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glioma

Share to Indoles

Share to MAP Kinase Signaling System

Share to Sulfonamides

Share to Survival Analysis

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27848137
DOI: 10.1007/s11060-016-2333-4
PMCID: PMC5560871

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.PMID 27848137Read ↗

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.Semantic proximity Read ↗

BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

BRAF mutation predicts sensitivity to MEK inhibition.Semantic proximity Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.Semantic proximity Read ↗

Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success.Semantic proximity Read ↗

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read ↗

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.